Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 2366 • ACR Convergence 2023
Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma
Hung Vo¹, Aarohi Mehendale², Anahita Pilvar³, Eugene Kissin⁴, Marcin Trojanowski⁵, Michael York⁶, Darren Roblyer² and Andreea Bujor⁶, ¹Boston Medical Center, Peabody, MA, ²Department of Biomedical Engineering, Boston University, Boston, MA, ³Department of Electrical and Computer Engineering, Boston University, Boston, MA, ⁴Boston University, Newton, MA, ⁵Boston University School of Medicine, Boston, MA, ⁶Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by excessive collagen deposition in the skin and internal organs, along with vascular dysfunction. The modified…
Abstract Number: 0332 • ACR Convergence 2023
Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis
Jeong Min Yu¹, John VanBuren², Angela Child², Jessica Alvey², Lisa Mandl³, Laura Pinheiro⁴, Shervin Assassi⁵, Elana Bernstein⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Faye Hant¹¹, Laura Hummers¹², Dinesh Khanna¹³, Kimberly Lakin¹, Dorota Lebiedz-Odrobina¹⁴, Yiming Luo¹⁵, Ashima Makol¹⁶, Jerry Molitor¹⁷, Duncan Moore¹⁸, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah²¹, Ankoor Shah²², Victoria Shanmugam²³, Brian Skaug²⁴, Virginia Steen²⁵, Elizabeth Volkmann²⁶ and Jessica Gordon¹, ¹Hospital for Special Surgery, New York, NY, ²University of Utah, Salt Lake City, UT, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine College, New York, NY, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Columbia University, New York, NY, ⁷Massachusetts General Hospital, Boston, MA, ⁸Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁹Scleroderma Research Foundation, Brisbane, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins University, Baltimore, MD, ¹³University of Michigan, Ann Arbor, MI, ¹⁴University of Utah, Cottonwood Heights, UT, ¹⁵Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁶Mayo Clinic, Rochester, MN, Rochester, MN, ¹⁷University of Minnesota, Minneapolis, MN, ¹⁸Northwestern Memorial Hospital, Chicago, IL, ¹⁹Northwestern University, Riverside, IL, ²⁰University of Pennsylvania, Philadelphia, PA, ²¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²²Duke University, Durham, NC, ²³Victoria Shanmugam, MD, Great Falls, VA, ²⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²⁵Georgetown University School of Medicine, Washington, DC, ²⁶University of California Los Angeles, Los Angeles, CA
Background/Purpose: Skin disease is a hallmark of systemic sclerosis (SSc). The modified Rodnan skin score (mRSS) is physician performed measurement that assesses the extent and…
Abstract Number: 1142 • ACR Convergence 2023
A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease
Nikita Jhawar, Claire Wilson, Andy Abril, Li Zhuo and Yaohua Ma, Mayo Clinic, Jacksonville, FL
Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but…
Abstract Number: 2595 • ACR Convergence 2023
A Randomized Controlled Trial to Compare the Efficacy and Safety of Tacrolimus with Mycophenolate Mofetil in Patients with Systemic Sclerosis – Interstitial Lung Disease ( INSIST TRIAL)
Shefali Khanna Sharma¹, Jithin Mathew¹, Chirag Kopp¹, Varun Dhir², Sahajal Dhooria³, Anindita Sinha¹ and Sanjay Jain¹, ¹Post Graduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³PGI CHANDIGARH, Chandigarh, India
Background/Purpose: Interstitial lung disease in systemic sclerosis(SSc-ILD) is heterogeneous with limited therapeutic options. Mycophenolate mofetil (MMF) is the most commonly used first line agent for…
Abstract Number: 0611 • ACR Convergence 2023
Demographics and Clinical Features Associated with Small Bowel Hypomotility in Systemic Sclerosis
Jenice Cheah¹, Jamie Perin², Michael Hughes³, Julie Paik⁴, Christopher Mecoli², Laura Hummers⁴, Ami Shah⁵, Fred Wigley⁶ and Zsuzsanna McMahan⁷, ¹University of California Los Angeles, Los Angeles, CA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ⁴Johns Hopkins University, Baltimore, MD, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁶Department of Rheumatology, Johns Hopkins Medicine, Baltimore, MD, ⁷Johns Hopkins Rheumatology, Lutherville, MD
Background/Purpose: The gastrointestinal (GI) tract is the second most commonly affected organ in patients with systemic sclerosis (SSc). It is estimated that the small bowel…
Abstract Number: 1516 • ACR Convergence 2023
Systemic Sclerosis Gastrointestinal Tract Vascular Biomarkers of Symptomatic Disease Activity
Venkateswara Gogulamudi¹, Sarah Wood², Elizabeth Johnson², Aaron Petrey³, Anthony Donato⁴ and Tracy Frech², ¹Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, ²Vanderbilt University Medical Center, Nashville, TN, ³University of Utah, Salt Lake City, UT, ⁴University of Utah and Salt Lake VAMC, Salt Lake City, UT
Background/Purpose: Gastrointestinal tract symptoms are common in systemic sclerosis (SSc). The Scleroderma Clinical Trials Consortium University of California Los Angeles Gastrointestinal Tract Questionnaire (GIT 2.0)…
Abstract Number: 0612 • ACR Convergence 2023
COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study
Kimberly Lakin¹, Jessica Gordon¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier², Richard Henry², Christopher Denton⁴, Luc Mouthon⁵, Robert Spiera⁶ and Brett Thombs², ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, ³Radboud University, Nijmegen, Netherlands, ⁴University College London, London, United Kingdom, ⁵Hopital Cochin - Paris University, Paris, France, ⁶Hosptial for Special Surgery, New York, NY
Background/Purpose: We previously surveyed individuals with systemic sclerosis (SSc) enrolled in Scleroderma Patient-centered Intervention Network (SPIN) Cohort between April-May 2021 to determine COVID-19 vaccination rates,…
Abstract Number: 1521 • ACR Convergence 2023
Microvascular Remodeling After Autologous Stem Cell Transplant for Systemic Sclerosis
Lisa Balistreri¹, Megan Sullivan¹, Florentina Berianu¹, Ernesto Ayala² and Andy Abril², ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic, Jacksonville, FL
Background/Purpose: Autologous hematopoietic stem cell therapy (HSCT) is an effective therapy for patients with rapidly progressive systemic sclerosis (SSc) refractory to standard therapies. The disease…
Abstract Number: 007 • 2023 Pediatric Rheumatology Symposium
Single Cell RNA Sequencing Analysis of the Skin to Evaluate the Effect of Autologous Stem Cell Transplant on Fibroblast Populations in Juvenile Onset Systemic Sclerosis
Claire Cheng, Giffin Werner, Anwesha Sanyal and Kathryn Torok, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Juvenile systemic sclerosis (JSSc) is a rare autoimmune disease associated with high morbidity. Inflammatory driven multi-organ fibrosis is similar to adult-onset SSc, with 40%…
Abstract Number: 086 • 2023 Pediatric Rheumatology Symposium
Systemic Sclerosis Overlap Syndrome: A Case Series from a Single Large Pediatric Center
Jessica Nguyen¹, Miriah Gillispie-Taylor¹, Eyal Muscal¹ and Marietta Deguzman², ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Childhood-onset systemic sclerosis (SSc) is a rare but potentially life-threatening autoimmune condition with features including immune, fibrotic, and vascular manifestations affecting the skin and…
Abstract Number: 106 • 2023 Pediatric Rheumatology Symposium
Caregivers’ Perspectives on Barriers to Care in Juvenile Localized and Systemic Scleroderma
Leigh Stubbs¹, Andrew Ferry², Danielle Guffey¹, Christina Loccke³, Erin Moriarty Wade³, Pamela Pour³, Kaveh Ardalan⁴, Peter Chiraseveenuprapund⁵, Ingrid Ganske⁶, Daniel Glaser⁷, Gloria Higgins⁸, Nadia Luca⁹, Katharine Moore¹⁰, Vidya Sivaraman¹¹, Katie Stewart¹, Natalia Vasquez Canizares¹², Raegan Hunt¹, Renata Maricevich¹, Kathryn Torok¹³ and Suzanne Li¹⁴, ¹Baylor College of Medicine, Houston, TX, ²Oregon Health and Science University, Portland, OR, ³n/a, ⁴Duke University School of Medicine, Durham, NC, ⁵University of California - San Diego, San Diego, CA, ⁶Boston Children’s Hospital and Harvard Medical School, Boston, MA, ⁷Yale University School of Medicine, New Haven, CT, ⁸Nationwide Childrens Hospital/ The Ohio State University, Columbus, OH, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Colorado / Children's Hospital Colorado, Denver, CO, ¹¹Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ¹²Children's Hospital at Montefiore, New York, NY, ¹³University of Pittsburgh, Pittsburgh, PA, ¹⁴Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ
Background/Purpose: Juvenile localized scleroderma (LS) and systemic sclerosis (SSc) are rare rheumatic diseases often associated with severe morbidities. Delays in diagnosis are common, putting children…
Abstract Number: 116 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort
Dawn Janysek¹, Yiressy Pina², Danielle Guffey³ and Marietta De Guzman¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Production of autoantibodies is a hallmark of SLE, with ANAs as a required diagnostic feature and anti-dsDNA and anti-Smith antibodies being disease-specific. Anti-Scl-70 antibodies…
Abstract Number: 0518 • ACR Convergence 2022
Changes in Skin Fibroblast Polarization Gene Expression Herald Clinical Improvement in Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter Lakin¹, Deanna Jannat-Khah, DrPH, MSPH¹, Yajas Shah², Olivier Elemento², Aliza Bloostein¹, Jessica Gordon¹, Michael Whitfield³, Barbara White⁴, Dana Orange⁵ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH, ⁴Corbus Pharmaceuticals, Pleasanton, CA, ⁵The Rockefeller University, New York, NY
Background/Purpose: We previously identified a group of genes associated with high alpha-smooth muscle actin (aSMA) and low CD34 fibroblast staining in lesional systemic sclerosis (SSc)…
Abstract Number: 2162 • ACR Convergence 2022
Systemic Sclerosis in Alaska Native/American Indian People in Alaska
Vivek Mehta and Elizabeth Ferucci, Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Systemic sclerosis (SSc) is known to have more severe manifestations and higher mortality in Black populations, while fewer studies have examined disparities in epidemiology…
Abstract Number: 1059 • ACR Convergence 2022
Vision Transformer Assisting Rheumatologists in Screening for Capillaroscopy Changes in Systemic Sclerosis: An Artificial Intelligence Solution
Alexandru Garaiman¹, Farhad Nooralahzadeh², Carina Mihai¹, Nikitas Gkikopoulos¹, Nicolas Perez Gonzalez², Mike Becker¹, Oliver Distler¹, Michael Krauthammer³ and Britta Maurer⁴, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Biomedical Informatics, University of Zurich, Zürich, Switzerland, ³Department of Quantitative Biomedicine, University of Zurich, Zürich, Switzerland, ⁴Department of Rheumatology and Immunology, University Hospital Bern, University of Bern, Bern, Switzerland
Background/Purpose: An accurate assessment of nailfold capillaroscopy (NFC) images has great importance in the diagnosis and prognosis of systemic sclerosis (SSc). To overcome some of…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.